This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Technology / Immatics presents PRAME clinical data
Tech medical breakthrough

Immatics presents PRAME clinical data

Analysis based on 6 articles · First reported Apr 21, 2026 · Last updated Apr 21, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The announcement of multiple oral presentations at a major oncology conference is a positive development for Immatics, potentially increasing investor confidence in its clinical pipeline. Positive data from these presentations could lead to a significant increase in Immatics' stock price and attract further investment in the biotechnology sector.

Biotechnology Pharmaceuticals
Event Summary

Immatics announced that all submitted abstracts for its clinical-stage programs have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held from May 29-June 2, 2026, in Chicago, Illinois, USA. The four presentations will include Phase 1b clinical data on anzu-cel in advanced cutaneous and uveal melanoma, updated Phase 1a/1b data for IMA203CD8 in gynecologic cancers, updated Phase 1 data on PRAME cell therapies in synovial sarcoma, and updated results for the MAGEA4/8 bispecific IMA401 across multiple cancers. These presentations highlight the continued advancement of Immatics' PRAME franchise and its focus on developing novel immunotherapies for patients with solid tumors.

Entities Involved
stock
Immatics
Immatics announced that its abstracts for four clinical-stage programs have been selected for oral presentations at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, highlighting the advancement of its PRAME franchise and potential for novel immunotherapies.
Importance 100.0 Sentiment 70.0
per
Davar Diwakar
Davar Diwakar is the presenting author for the anzu-cel clinical response dynamics in advanced melanoma.
Importance 20.0 Sentiment 0.0
per
Antonia Busse
Antonia Busse is the presenting author for the IMA203CD8 study results in ovarian cancer.
Importance 20.0 Sentiment 0.0
per
Dejka M. Araujo
Dejka M. Araujo is the presenting author for the PRAME-directed T-cell receptor T-cell therapies in synovial sarcoma.
Importance 20.0 Sentiment 0.0
per
Martin Wermke
Martin Wermke is the presenting author for the first-in-human results with IMA401.
Importance 20.0 Sentiment 0.0
ngo
American Society of Clinical Oncology
Importance 0.0 Sentiment 0.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.